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a  b  s  t  r  a  c  t
The  alpha-linolenic  acid (ALA)-diacylglycerol  (DAG)  oil is  an edible  oil  enriched  with  DAG  (>80%)  and  ALA
(>50%).  Although  DAG  oil,  which  mainly  consists  of  oleic  and  linoleic  acids  has  no  genotoxic  concerns,  the
fatty  acid  composition  could  affect  the  chemical  property  of DAG.  Therefore,  the  purpose  of this  study
was  to evaluate  the  genotoxicity  of ALA-DAG  oil  using  standard  genotoxicity  tests  in accordance  with
the  OECD  guidelines.  ALA-DAG  oil showed  negative  results  in  the bacterial  reverse  mutation  test  (Ameseywords:
lpha-linolenic acid-rich diacylglycerol
iacylglycerol
lpha-linolenic acid
atty acid composition
test)  and  in vitro  micronucleus  test  in  cultured  Chinese  hamster  lung  cells  with  and  without  metabolic
activation,  and  in the in  vivo  bone  marrow  micronucleus  test  in  mice.  Our  results  did  not  show  any
genotoxicity,  suggesting  that  the  fatty  acid  composition  had  no deleterious  effects.  We  conclude  that
ALA-DAG  oil  had  no  genotoxicity  concerns  under  the  testing  conditions.
© 2016  The  Author(s).  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the  CC
enotoxicity
. Introduction
Diacylglycerol (DAG; Fig. 1a) is a natural component found in
arious edible oils and has been widely consumed for numerous
ears in the human diet. Recently, a high-purity DAG oil (DAG
ontent >80%) was enzymatically prepared from plant oils for com-
ercial use [1]. Several clinical studies focusing on the beneﬁcial
ealth effect of DAG oil in humans have revealed that it could have
 preventive effect on body fat accumulation [2,3].
The fatty acid composition of dietary oils is considered to affect
heir physiological action. For example, dietary (n-3) polyunsatu-
ated fatty acids showed beneﬁcial effects on lipid metabolism and
mmune response in previous studies [4–8]. Among them, alpha-
inolenic acid (ALA; Fig. 1b) has been reported to decrease the blood
ipid concentration and reduce body and fat weight [1,6,9–12]. In
act, DAG oil, which mainly contains ALA as the constitutive fatty
Abbreviations: 2AA, 2-aminoanthracene; 9AA, 9-aminoacridine hydrochloride
ydrate; AF-2, 2-(2-furyl)-3-(5-nitro-2-furyl)acrylamide; ALA, alpha-linolenic acid;
(a)P, benzo(a)pyrene; CLC, Colchicine; CP, cyclophosphamide; DAG, diacylglyc-
rol; DMSO, dimethyl sulfoxide; ICH, International Conference on Harmonisation
f Technical Requirements for Registration of Pharmaceuticals for Human Use; LA,
inolenic acid; MMC, mitomycin C; MNPCE, micronucleated polychromatic erythro-
yte; NaN3, sodium azide; NCE, normochromatic erythrocyte; TAG, triacylglycerol.
∗ Corresponding authors.
E-mail addresses: honda.hiroshi@kao.co.jp (H. Honda), ito.yuichi@kao.co.jp
Y. Ito).
1 These authors contributed equally.
ttp://dx.doi.org/10.1016/j.toxrep.2016.08.001
214-7500/© 2016 The Author(s). Published by Elsevier Ireland Ltd. This is an open acces
c-nd/4.0/).BY-NC-ND license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
acid (ALA-DAG oil; Fig. 1), is beneﬁcial for suppressing body weight
gain and fatty liver [13–15]. Ando et al. [16] recently reported that
ALA-DAG oil has a superior effect on the postprandial fat oxida-
tion compared to oleic and linoleic acid-rich DAG. It suggests that
the conjugation between ALA and DAG could affect the chemical
properties of each conjugant and might increase their inherent
physiological activity. Therefore, the toxicokinetics and dynamics
of ALA-conjugated DAG might differ from those of DAG conjugated
with other fatty acids.
The safety evaluations of DAG oil containing oleic and linoleic
acids have mainly focused on the acute and repeated toxicity
[17,18], developmental and reproductive toxicity [19], genotoxi-
city, carcinogenicity [20,21], and high-dose dietary DAG oil clinical
studies [22], all of which have demonstrated no adverse effects.
Although glycidol fatty acid esters (GEs) found in DAG oil as
process-related contaminants led to safety concerns about the
possible release of glycidol [23], an animal genotoxic-carcinogen,
during the digestion, the internal exposure levels of glycidol in
DAG-oil exposed subjects were considered negligible [24–26].
However, little is currently known about the toxicity including
genotoxicity of ALA-DAG oil itself and the potential toxicological
role of the fatty acid composition of DAG because the ALA content
of the previously tested DAG oils tested was low (8.7%) [21].
Although ALA showed no genotoxicity in the bacterial reverse
mutation test (Ames test) and mouse lymphoma test performed by
the National Toxicology Program (NTP) [27,28], a slight increase in
the revertant colonies was  observed under previous experimental
s article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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F acylglycerol (ALA-DAG) oil. a. Diacylglycerol (DAG), R: One of the fatty acids in Table 1. b.
A  edible oil enriched with DAG (>80%), and ALA (>50%) as a fatty acid composition.
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Table 1
Glycerol and fatty acid composition of alpha-linolenic acid-diacylglycerol (ALA-
DAG) oil.
Components of ALA-DAG oil wt%
Ester distribution
Monoglyceride 0.7
Diglyceride (DAG) 83.1
Triglyceride and othersa 16.2
Fatty acid composition
Palmitic acid 2.2
Stearic acid 1.2
Oleic acid 21.4
Linoleic acid 16.5
Linolenic acid 57.6ig. 1. Diacylglycerol (DAG), alpha-linolenic acid (ALA), and alpha-linolenic acid-di
lpha-linolenic acid (ALA). Alpha-linolenic acid (ALA)-diacylglycerol (DAG) oil is an
onditions. This effect was considered non-genotoxic because the
esponse was either very weak or observed only at a dose range
eyond that recommended by the Organisation for Economic Co-
peration and Development (OECD) guideline [29]. However, as
escribed earlier, the fatty acid composition (ALA content) could
ffect the chemical properties of DAG. Thus, the genotoxicity of
LA-DAG oil needs to be evaluated. Since it is difﬁcult to compare
he in vitro experimental doses used in genotoxicity tests with the
LA-DAG oil intake in human, an in vivo genotoxicity assay would
e useful for quantitative risk evaluation.
The present study was speciﬁcally focused on the effect of the
atty acid composition of DAG oil on its potential genotoxicity. The
LA-DAG oil was investigated using in vitro and in vivo genotoxicity
ests, which are accepted by the OECD guideline.
. Materials and methods
.1. Test chemicals and bacterial strains
The chemicals used as positive controls included: 2-(2-furyl)-3-
5-nitro-2furyl)acrylamide (AF-2), 2-aminoanthracene (2AA), and
odium azide (NaN3), purchased from Wako Pure Chemical Indus-
ries, Ltd., (Osaka, Japan); and 9-aminoacridine hydrochloride
ydrate (9AA), purchased from Sigma-Aldrich Chemical Corp, Inc.,
St. Louis, MO,  USA). Mitomycin C (MMC), cyclophosphamide
onohydrate (CP), and colchicine (CLC) were purchased from
yowa Hakko Kirin Co., Ltd., (Tokyo, Japan), Sigma-Aldrich Chem-
cal Corp, Inc., (St. Louis, MO,  USA), and Wako Pure Chemical
ndustries, Ltd., (Osaka, Japan), respectively. The olive oil used
s a negative control in the bone marrow micronucleus assay in
ice was purchased from Wako Pure Chemical Industries, Ltd.
Osaka, Japan). The bacterial strains Salmonella typhimurium and
scherichia coli were obtained from the National Institute of Tech-
ology and Evaluation (Chiba, Japan).
.2. Study design
All studies were performed in compliance with the Good Labo-
atory Practice (GLP) regulations and in accordance with the OECD
uidelines for the Testing of Chemicals No. 471, 474, and 487
29–31]. There were no deviations from the guidelines..3. Preparation of ALA-DAG oil
The ALA-DAG oil was synthesized by esterifying glycerol with
atty acids obtained from linseed oil using immobilized lipase asa The level of GEs in the ALA-DAG oil was comparable to that in the other edible
oils (<0.3 g/g) [34].
previously described [32]. The fatty acid and glycerol composi-
tion of the test oils are shown in Table 1. We  used the Deutsche
Gesellschaft für Fettwissenschaft (DGF) standard method [33] to
conﬁrm that the level of GEs in the ALA-DAG oil was comparable
to that of the other edible oils (<0.3 g/g) [34].
2.4. Bacterial reverse mutation test (Ames test)
To evaluate the mutagenicity of the ALA-DAG oil, a bacterial
reverse mutation test (Ames test) was performed with ﬁve bacterial
test strains (S. typhimurium: TA100, TA1535, TA98, and TA1537; and
E. coli: WP2uvrA) using a pre-incubation method with and without
metabolic activation. Dimethyl sulfoxide (DMSO) was  used as the
solvent control, and the positive controls were AF-2, NaN3, 9AA
(without metabolic activation), and 2AA (with metabolic activa-
tion).
2.4.1. Dose selection
The study consisted of two  independent tests, which were the
dose-ﬁnding test and the main test. The highest dose was  set at
5000 g/plate for the dose-ﬁnding test in accordance with the
OECD guidelines [29], and the lower doses were set at a com-
mon  ratio of approximately 3. In the dose-ﬁnding test, we did not
observe a ≥ 2-fold or dose-dependent increase in the number of
revertant colonies for the test substances compared to that in the
negative control group. Furthermore, there was no growth inhi-
bition of any of the test strains at up to 5000 g/plate with and
without metabolic activation. Therefore, the highest dose was set
at 5000 g/plate for the main test while the lower doses were set
at a common ratio of 2.
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.4.2. Experimental procedure
The genotoxicity test was performed using a pre-incubation
ethod [35] with and without metabolic activation. Brieﬂy, 0.5 mL
f either 0.1 mol/L sodium phosphate buffer (pH 7.4) or the S9 mix
for treatment without or with metabolic activation, respectively),
nd 0.1 mL  of the bacterial suspension were added to a test tube.
hen, 0.1 mL  of the test substance preparation was  added, the mix-
ure was incubation at 37 ◦C for 20 min, 2 mL  of the top agar was
dded to the test tube, and the mixture was overlaid onto a mini-
al  glucose agar plate. The plates were subsequently placed in an
ncubator at 37 ◦C for 48 h and the revertant colonies were counted.
The S9 fraction (Oriental Yeast Co. Ltd., Tokyo, Japan) for the
etabolic activation was prepared from phenobarbital and 5,6-
enzoﬂavone-induced Sprague-Dawley rats. Subsequently, the S9
ix  was prepared by mixing 1 vol of the S9 fraction with 9 vols of
ofactor-I (Oriental Yeast Co. Ltd., Tokyo, Japan) dissolved in water
as the nicotinamide adenine dinucleotide phosphate (NADPH)
egenerating system).
.4.3. Determination criteria
A response was determined as positive when the test chemi-
al caused a ≥ 2-fold dose-dependent increase in the mean number
f revertant colonies per plate compared to the negative control
ollowed by conﬁrmation that the two independent tests were
eproducible.
.5. In vitro micronucleus test in cultured cells
To evaluate the micronuclei-inducing potential of the ALA-DAG
il in in vitro, the micronucleus test was performed using CHL/IU
ells with short-term treatment with and without metabolic acti-
ation and continuous treatment for 24 h.
.5.1. Grouping and dose selection
For the treatment of cells, the ALA-DAG oil was suspended in
% DMSO as ﬁnal concentration. Based on the results of the dose-
nding test, the highest dose level was set at 2000 g/mL, while
he lower levels of 1000 and 500 g/mL were set at a common
atio of 2 because no marked cytotoxicity was observed at up to
000 g/mL regardless of the treatment condition. Additional doses
f 25 and 50 g/mL were set for the short-term and continuous
reatments, respectively, at which no test substance precipitation
as anticipated at the end of treatment. DMSO was  used as the
egative control, whereas CP and MMC  were the positive controls
or determining the clastogenicity of treatments with and with-
ut metabolic activation, respectively. CLC was used as the positive
ontrol for determining the aneugenicity of treatment without
etabolic activation.
.5.2. Experimental procedure
The CHL/IU cells were plated at a density of 1 × 104 cells/mL and
ncubated for approximately 72 h. For the short-term treatment, the
ells were treated with the ALA-DAG oil or control chemicals for 3 h
ith or without metabolic activation. Subsequently, the cells were
ashed and incubated in fresh medium for 21 h (the total exper-
mental period was 24 h, which was equivalent to 1.5 cell cycles).
or the metabolic activation condition, the S9 mix  (ﬁnal S9 concen-
ration of 5%) was used at a ﬁnal medium concentration of 16.7%.
he S9 mix  for the metabolic activation was prepared in a similar
anner to that used for the Ames test. For the continuous treat-
ent, the cells were treated with each concentration for 24 h. The
umber of viable cells was determined for all the conditions when
he treatment was started and when the micronuclei specimens
ere prepared, as an indication of the effects of treatment on cell
roliferation. Furthermore, the cell numbers were used to calcu-
ate the relative increase in cell count (RICC), which is described inports 3 (2016) 716–722
the OECD Test Guideline 487 [30]. After the treatment, the cells
were harvested, suspended in 0.075 M potassium chloride (KCl)
solution for 10 min, ﬁxed with Carnoy’s ﬁxative solution (in a 3:1
mixture of methanol and acetic acid), and then mounted onto clean
glass slides. The specimens were stained with acridine orange solu-
tion and 4000 mononuclear cells per group (2000 cells/dish) were
examined. The number and incidence (%) of mononuclear cells with
micronuclei were scored in each group.
2.5.3. Statistical analysis and determination criteria
Fisher’s exact test with Bonferroni correction was performed to
determine whether the number of cells with micronuclei differed
signiﬁcantly between the negative control and the ALA-DAG-
treated groups using the statistical analysis software (SAS) System,
Release 9.2 (SAS Institute Inc., NC, USA). A signiﬁcance level of 5%
(one-sided) was  used in the present study.
2.6. Bone marrow micronucleus test in mice
To evaluate the micronuclei-inducing potential of the ALA-DAG
oil in in vivo, a bone marrow micronucleus test was performed using
male Crl:CD1(ICR) mice.
2.6.1. Grouping and administration
A previous in vivo micronucleus test conducted on DAG oil [21]
showed no changes in clinical signs or body weight at a dose of
2000 mg  kg−1 day−1, which is the upper limit dose speciﬁed in
the OECD Guidelines for the Testing of Chemicals [31]. Therefore,
2000 mg  kg−1 day−1 was set as the highest dose in the micronu-
cleus test in the present study, while the lower doses were 1000
and 500 mg  kg−1 day−1 with a common ratio of 2. Furthermore,
olive oil and MMC  were used as the negative and positive controls,
respectively.
2.6.2. Experimental procedure
The different doses of the ALA-DAG oil were resuspended in
olive oil and the 8-week-old male ICR (Crl:CD1) mice were treated
with two oral doses by gavage, which were administered 24 h apart.
The olive oil (negative vehicle control) was  administered in the
same manner as the ALA-DAG oil, while the MMC  solution (pos-
itive control) was  intraperitoneally administered as a single dose
at 2 mg  kg−1 day−1.
The bone marrow smears were prepared from all the surviv-
ing animals 24 h after the last administration and were stained
with acridine orange. The specimens were examined by using ﬂuo-
rescent microscopy to observe 4000 polychromatic erythrocytes
(PCEs) and the number of micronucleated PCEs (MNPCEs) was
counted. Then, 500 total erythrocytes (PCEs + normochromatic ery-
throcytes) from each animal were observed and the proportion of
the PCEs was determined as an indicator of the suppression of bone
marrow cell proliferation.
2.6.3. Statistical analysis and determination criteria
The method of Kastenbaum and Bowman [36] was used to deter-
mine any signiﬁcant difference in the number of MNPCEs between
the negative control group and each ALA-DAG oil-treated or the
positive control groups. To analyze the incidence of PCE formation,
Dunnett’s multiple comparison test was performed to compare the
negative control group and each ALA-DAG oil-treated group, and
Student’s t-test was used to compare the negative and positive
control groups. These statistical analyses were performed at a sig-
niﬁcance level of 5% for both the one-tailed tests performed using
the method of Kastenbaum and Bowman [36] and the two-tailed
tests performed using the SAS software.
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Table  2
Bacterial reverse mutation test (Ames test) of alpha-linolenic acid-diacylglycerol (ALA-DAG) oil (main test).
S9 mix Group Dose (g/plate) Number of revertant colonies/plate
Base-pair substitution mutations Frameshift mutations
TA100 TA1535 WP2uvrA TA98 TA1537
− Negative control DMSO – 88 ± 2 10 ± 1 22 ± 1 17 ± 3 6 ± 1
ALA-DAG oil 313 103 ± 5 8 ± 0 23 ± 3 15 ± 1 5 ± 1
625  89 ± 5 7 ± 2 21 ± 4 15 ± 3 6 ± 1
1250 85 ± 3 8 ± 2 20 ± 3 15 ± 2 6 ± 1
2500a 95 ± 11 8 ± 2 20 ± 3 15 ± 2 5 ± 1
5000a 87 ± 3 5 ± 1 22 ± 2 13 ± 1 5 ± 1
+ Negative control DMSO – 103 ± 2 8 ± 1 25 ± 3 23 ± 3 8 ± 1
ALA-DAG oil 313 100 ± 4 7 ± 1 21 ± 3 24 ± 4 8 ± 1
625  104 ± 7 6 ± 0 25 ± 2 26 ± 3 6 ± 1
1250 117 ± 5 9 ± 1 25 ± 4 21 ± 1 7 ± 1
2500a 112 ± 4 8 ± 1 24 ± 4 24 ± 4 9 ± 2
5000a 116 ± 5 10 ± 2 27 ± 3 25 ± 4 8 ± 2
− Positive  controls
AF-2 0.01 468 ± 18
NaN3 0.5 279 ± 13
AF-2 0.02 361 ± 15
AF-2  0.1 456 ± 26
9AA  80 189 ± 6
+ Positive  controls
2AA 1 615 ± 19
2AA 2 219 ± 12 118 ± 19
2AA  10 312 ± 37
2AA  0.5 406 ± 15
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1a Test substance precipitation (on plates after 48 h incubation), DMSO: dime
ydrochloride hydrate, NaN3: sodium azide, 2AA: 2-aminoanthracene.
. Results
.1. Ames test
The results of the main Ames test of the ALA-DAG oil using the
ve bacterial strains are shown in Table 2. The dose range for the
ose-ﬁnding test was determined in the presence or absence of
etabolic activation at doses of 15–5000 g/plate at a common
atio of approximately 3. Based on the results of the dose-ﬁnding
est, the main test was conducted using doses of 313–5000 g/plate
t a common ratio of 2. No bacterial toxicity was observed at
ny of the tested doses. The positive controls were simultane-
usly evaluated under the standard Ames test conditions during
ll the experiments and showed marked positive responses, which
alidated the test results. The test chemical was precipitated at
1250 g/plate with and without metabolic activation.
The ALA-DAG oil did not cause a > 2-fold increase in the number
f colonies/plate compared to the negative control in both the dose-
nding test and main test. The results suggested that ALA-DAG oil
as no mutagenic effect under the conditions of the present study.
.2. In vitro micronucleus test
The result of the in vitro micronucleus test to determine the
ffects of the ALA-DAG oil in the CHL/IU cells is summarized in
able 3. We  determined that this experiment was  performed satis-
actorily because (1) the proportion of cells with micronuclei was
igniﬁcantly increased in the positive control group and (2) the
icronucleus analysis was possible for the three dose levels. The
LA-DAG oil did not exhibit cytotoxicity under any of the treatment
onditions. In the short-term treatment without metabolic activa-
ion, the proportions of cells with micronuclei in the 25, 500, 1000,
nd 2000 g/mL-treated groups were 1.9, 1.8, 1.9, and 1.8%, respec-
ively, and there was no signiﬁcant difference compared with that
n the negative control group (1.5%). The corresponding propor-
ions of micronucleated cells with metabolic activation were 1.4,
.5, 1.7, and 1.9%, respectively, and no signiﬁcant difference wasulfoxide, AF-2: 2-(2-furyl)-3-(5-nitro-2-furyl)acrylamide, 9AA: 9-aminoacridine
observed compared with the negative control group (1.3%). Simi-
larly, following continuous treatment for 24 h, the proportions of
the micronucleated cells in the 50, 500, 1000, and 2000 g/mL-
treated cells were 1.4, 1.5, 1.8, and 1.8%, respectively, which was
comparable to that in the negative control group (1.8%). Taken
together, these ﬁndings demonstrate that the ALA-DAG oil was not
clastogenic and aneugenic in the CHL/IU cells.
3.3. Bone marrow micronucleus test
The results of the bone marrow micronucleus test to determine
the effect of ALA-DAG oil in mice are presented in Table 4. There
was no signiﬁcant increase in the incidence of MNPCEs or PCEs
in the test substance-treated groups compared with the vehicle
control group. The positive control, MMC,  remarkably increased
the incidence of MNPCEs (P < 0.05). Therefore, under the experi-
mental conditions of the present study, ALA-DAG oil did not show
clastogenic or aneugenic effects in in vivo.
4. Discussion
The results of the present study indicate that the ALA-DAG oil
did not induce any genotoxic effects, because it did not show muta-
genicity in the Ames test, or clastogenicity and aneugenicity in
the in vitro and in vivo micronucleus tests. In the series of geno-
toxicity tests, the highest doses used were the maximum levels
recommended by the OECD guidelines. Furthermore, the nega-
tive and positive controls used in each test exhibited the expected
responses, validating the methodologies used. As a mammalian
genotoxicity test, the in vitro micronucleus test was used to detect
the aneugenicity and clastogenicity in the present study, because
the in vitro chromosomal aberration test might not detect the aneu-
genicity adequately [37]. The results revealed that the ALA-DAG oil
was not aneugenic and clastogenic in both the in vivo and in vitro
micronucleus tests.
The GEs found in the DAG oil as an impurity have raised safety
concerns about the possible release of glycidol [23,38], an animal
720 H. Honda et al. / Toxicology Reports 3 (2016) 716–722
Table 3
In vitro micronucleus test of alpha-linolenic acid-diacylglycerol (ALA-DAG) oil in CHL/IU cells.
Treatment time – recovery time (hour) S9 mix Group Concentration (g/mL) RICC (%)a Micro-mononucleated cellsb
No. Incidence(%)
3–21 − Negative control
DMSO
100 59 1.5
ALA-DAG oil 25 108.0 77 1.9
500#† 104.0 73 1.8
1000#† 94.0 74 1.9
2000#† 92.0 72 1.8
Positive controls
MMCc 0.1 94.0 500 12.5
CLCd 0.75 58.0 255 6.4
3–21 + Negative control
DMSO
100 51 1.3
ALA-DAG oil 25 91.2 56 1.4
500#† 98.5 60 1.5
1000#† 98.5 66 1.7
2000#† 104.4 77 1.9
Positive control
CPc 10 66.2 946 23.7
24–0 −  Negative control
DMSO
100 72 1.8
ALA-DAG oil 50# 95.7 56 1.4
500#† 97.8 60 1.5
1000#† 82.6 73 1.8
2000#† 91.3 70 1.8
Positive controls
MMCc 0.025 89.1 324 8.1
CLCd 0.1 47.8 537 13.4
-:Without metabolic activation, +: with metabolic activation, RICC: relative increase in cell count, DMSO: dimethyl sulfoxide, MMC:  mitomycin C, CLC: colchicine, CP:
cyclophosphamide monohydrate, precipitation in treatment medium was observed at #start and †end of treatments.
a Relative values when RICC in negative control was  considered as 100%.
b total of 4000 mononucleated cells were scored in each group.
c For clastogenicity.
d For aneugenicity.
Table 4
Bone marrow micronucleus test of alpha-linolenic acid-diacylglycerol (ALA-DAG) oil in mice.
Group Dose (mg  kg−1 day−1) PCEsc MNPCEsd
No. Incidence (%) No. Incidence (%)
Mean ± SD Mean ± SD
Negative control Olive oila – 1362 54.48 ± 2.58 22 0.11 ± 0.03
ALA-DAG oila 500 1416 56.64 ± 2.78 27 0.14 ± 0.05
ALA-DAG oil 1000 1417 56.68 ± 2.81 27 0.14 ± 0.05
ALA-DAG oil 2000 1395 55.80 ± 3.46 28 0.14 ± 0.05
Positive control MMCb 2 1207 48.28$ ± 5.14 1219# 6.10 ± 1.15
MMC: mitomycin C, PCEs: polychromatic erythrocytes, MNPCEs: micronucleated polychromatic erythrocytes.
a treated twice by oral gavage administered 24 h apart.
b treated once by intraperitoneal injection.
c total of 2500 erythrocytes scored in each group.
one-ta
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Yd total of 20000 PCE scored in each group.
$ (p < 0.05 compared with negative control, Student’s t-test (two-tailed).
# p < 0.05 compared with negative control, Kastenbaum and Bowman’s method (
enotoxic-carcinogen, during the digestion process. Accordingly,
n a previous study, we demonstrated that the genotoxicity of GEs
ould depend on the release of glycidol [39]. Furthermore, the
otal levels of the GEs in ALA-DAG oil (<0.3 g/g) were equivalent
o the level of other edible oils [34], which are considered non-
enotoxic, and other potential genotoxic contaminants have not
een reported, indicating that it was not necessary to consider the
otential genotoxicity of contaminants in ALA-DAG oil.
ALA and its related substances have been reported to increase
evertant colonies in the Ames test with metabolic activation. For
xample, NTP [28] reported that a slight increase in the revertant
olonies was observed in the experiments with the TA97 and TA100
trains at ≥666 and ≥6000 g/plate at maximum fold ratios of
.71 and approximately 2 (with metabolic activation), respectively.
amaguchi and Yamashita [40] reported that autoxidized linoleniciled).
acid increased the number of revertant colonies in the Ames test
using TA98 and TA100 with metabolic activation. Similarly, Hage-
man et al. [41] reported that linoleic acid (LIA) peroxide showed
a mutagenic response in TA97 and TA100 strains in the Ames test
with metabolic activation. They suggested that there was a relation-
ship between the secondary autoxidation of LIA by the S9 mix  and
bacterial mutagenicity. These studies suggest that the peroxide pro-
duced by the secondary autoxidation induced by the S9 mix  might
have increased the revertant colonies in the Ames test to evaluate
the ALA-related compounds. The disposition of ALA-DAG oil could
change compared to that of ALA, which raises concerns that DNA-
reactive peroxides could easily be produced by the liver enzymes in
the DAG form of the oil. However, Katsuta et al. [42] reported that
the glyceride structure did not affect the amount and composition
of volatile aldehydes produced by oxidation of edible oils during
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rying. Similarly, in the present study, an increase in the number of
evertant colonies was not observed with the TA100 or TA98 strains
p to at least 5000 g/plate, which indicates no enhancement of
he bacterial mutagenicity. Therefore, we considered that the con-
ern over the potential production of reactive peroxides from the
LA-DAG oil was unfounded.
Although the fatty acid composition of oils has been known to
ffect their efﬁcacy [5–8,13–16], the effect of a difference in the
atty acid composition of DAG on its associated adverse effects has
ot been previously investigated. Therefore, a concern was raised
hat the conjugation between ALA and DAG could affect the chem-
cal properties of DAG and might induce different adverse effect
rom those of DAG with other fatty acid compositions. However,
esults of this study indicate that DAG would be non-genotoxic even
f ALA contents in the fatty acid composition increased up to 60%.
oreover, we examined the possibility that genotoxic substances
ould be generated via metabolic activation of ALA-DAG oil in the
n vitro studies in the presence and absence of a rat S9 mix  as well
s in vivo evaluations and identiﬁed no genotoxic effects under all
he test conditions used.
Assuming a 50 kg human takes 15 g of ALA-DAG oil as an edible
il, the daily intake of ALA-DAG oil is estimated to be 300 mg/kg.
his intake level is approximately 7 times lower than the highest
ose, 2000 mg/kg, used in the in vivo micronucleus test using mice.
n addition, since the intake of ALA-DAG oil may  be divided into
everal times in a day, the concentration of glycerides originating
rom ALA-DAG oil in the blood would be lesser than those of the
dministered dose to mice in the in vivo micronucleus test. There-
ore, it is unlikely to show genotoxicity in humans under the normal
se of edible oil. However, considering the possible difference in
oxicokinetics for different species, uncertainty of excess intake on
enotoxicity should be considered for precise risk assessment of
he ALA-DAG oil.
Triacylglycerol and DAG are essential nutritional components
f foods that have been consumed by humans for many years. The
osmetic ingredient review panels concluded that triacylglycerol is
ssentially non-genotoxic based on safety assessments [43]. More-
ver, a previous study demonstrated that DAG oil has a comparable
enotoxicity proﬁle to that of triacylglycerol [21].
Thus, from the results of this study, we concluded that the ALA-
AG oil showed no evidence of genotoxicity under the conditions
nvestigated. The genotoxicity proﬁle of ALA-DAG oil was  compara-
le to those of triacylglycerol, DAG, and ALA, suggesting its relative
afety.
unding
The present study was funded by KAO Corporation. H.H., Y.F.,
.I., Y.I., and O.M. are employees of Kao Corporation, which had
arketed the DAG oil described in this paper.
cknowledgement
We would like to thank Dr. Rika Homma, Health Care Products
esearch Laboratories for preparing the ALA-DAG oil.
eferences
[1] D. Von Der Haar, A. Stäbler, R. Wichmann, U. Schweiggert-Weisz,
Enzyme-assisted process for DAG synthesis in edible oils, Food Chem. 176
(2015) 263–270, http://dx.doi.org/10.1016/j.foodchem.2014.12.072.
[2] T. Nagao, N. Goto, Y. Fukushima, K. Onizawa, Dietary diacylglycerol
suppresses accumulation of body fat compared to triacylglycerol in men in a
double-blind controlled trial, J. Nutr. 130 (4) (2000) 792–797.
[3] H. Watanabe, T. Nagao, N. Goto, Y. Fukushima, K. Onizawa, H. Taguchi, T.
Ohmachi, T. Yasukawa, S. Naito, H. Shimasaki, H. Itakura, Long- term effects of
dietary diacylglycerols on body fat metabolism in man, J. Jpn. Oil Chem. Soc.
47 (1998) 369–376, 388. 10.5650/jos1996.47.369.
[ports 3 (2016) 716–722 721
[4] K.B. Kim, Y.A. Nam, H.S. Kim, A.W. Hayes, B.M. Lee, -linolenic acid:
nutraceutical, pharmacological and toxicological evaluation, Food Chem.
Toxicol. 70 (2014) 163–178, http://dx.doi.org/10.1016/j.fct.2014.05.009.
[5]  L.S. Harbige, Fatty acids, the immune response, and autoimmunity: a question
of  n-6 essentiality and the balance between n-6 and n-3, Lipids 38 (2003)
323–341, http://dx.doi.org/10.1007/s11745-003-1067-z.
[6] T. Ide, Effect of dietary —linolenic acid on the activity and gene expression of
hepatic fatty acid oxidation enzymes, Biofactors 13 (2000) 9–14.
[7] T.A. Mori, D.Q. Bao, V. Burke, I.B. Puddey, G.F. Watts, L.J. Beilin, Dietary ﬁsh as
a  major component of a weight-loss diet: effect on serum lipids, glucose, and
insulin metabolism in overweight hypertensive subjects, Am.  J. Clin. Nutr. 70
(1999) 817–825.
[8] I. Niot, J. Gresti, J. Boichot, G. Semporé, G. Durand, J. Bézard, P. Clouet, G.
Sempore, G. Durand, B. Jean, P. Clouet, Effect of dietary n-3 and n-6
polyunsaturated fatty acids on lipid-metabolizing enzymes in obese rat liver,
Lipids 29 (1994) 481–489.
[9] C.S. Hun, K. Hasegawa, T. Kawabata, M.  Kato, T. Shimokawa, Y. Kagawa,
Increased uncoupling protein2 mRNA in white adipose tissue, and decrease in
leptin, visceral fat, blood glucose, and cholesterol in KK-Ay mice fed with
eicosapentaenoic and docosahexaenoic acids in addition to linolenic acid,
Biochem. Biophys. Res. Commun. 259 (1999) 85–90, http://dx.doi.org/10.
1006/bbrc.1999.0733.
10] S. Ikemoto, M.  Takahashi, N. Tsunoda, K. Maruyama, H. Itakura, O. Ezaki,
High-fat diet-induced hyperglycemia and obesity in mice: differential effects
of dietary oils, Metabolism 45 (1996) 1539–1546.
11] T. Kawada, S. Kayahashi, Y. Hida, K. Koga, Y. Nadachi, T. Fushiki, Fish (bonito)
oil  supplementation enhances the expression of uncoupling protein in brown
adipose tissue of rat, J. Agric. Food Chem. 46 (1998) 1225–1227, http://dx.doi.
org/10.1021/jf9711000.
12] N. Tsuboyama-Kasaoka, M.  Takahashi, H. Kim, O. Ezaki, Up-regulation of liver
uncoupling protein-2 mRNA by either ﬁsh oil feeding or ﬁbrate
administration in mice, Biochem. Biophys. Res. Commun. 257 (1999)
879–885, http://dx.doi.org/10.1006/bbrc.1999.0555.
13] T. Murase, M.  Aoki, I. Tokimitsu, Supplementation with alpha-linolenic
acid-rich diacylglycerol suppresses fatty liver formation accompanied by an
up-regulation of beta-oxidation in Zucker fatty rats, Biochim. Biophys. Acta:
Mol.  Cell Biol. Lipids 1733 (2005) 224–231, http://dx.doi.org/10.1016/j.bbalip.
2004.12.015.
14] T. Murase, A. Nagasawa, J. Suzuki, T. Wakisaka, T. Hase, I. Tokimitsu, Dietary
alpha-linolenic acid-rich diacylglycerols reduce body weight gain
accompanying the stimulation of intestinal beta-oxidation and related gene
expressions in C57BL/KsJ-db/db mice, J. Nutr. 132 (2002) 3018–3022.
15] A. Takei, Y. Katsuragi, C. Abe, K. Mori, Y. Takeda, Y. Seo, H. Takase, H.
Takahashi, M.  Tohata, A. Chikama, S. Fumoto, S. Meguro, Y. Komine, T. Nagao,
T.  Hase, I. Tokimitsu, H. Shimasaki, H. Itakura, Effects of dietary -linolenic
acid-rich diacylglycerol on body fat in man (1): Lowering effect on body fat, J.
Oleo Sci. 50 (2001) 735–746, http://dx.doi.org/10.5650/jos.50.735.
16] Y. Ando, S. Saito, S. Oishi, N. Yamanaka, M.  Hibi, Alpha Linolenic Acid-enriched
Diacylglycerol Enhances Postprandial Fat Oxidation in Healthy Subjects: A
Randomized Double-blind Controlled Trail 2016, (2016) 1–7.
17] O. Morita, Y. Tamaki, J.B. Kirkpatrick, C.P. Chengelis, Safety assessment of
heated diacylglycerol oil: subchronic toxicity study in rats, Food Chem.
Toxicol. 46 (2008) 2748–2757, http://dx.doi.org/10.1016/j.fct.2008.04.031.
18] M.G. Soni, H. Kimura, G.A. Burdock, Chronic study of diacylglycerol oil in rats,
Food Chem. Toxicol. 39 (2001) 317–329, http://dx.doi.org/10.1016/S0278-
6915(00)00140-X.
19] O. Morita, J.F. Knapp, Y. Tamaki, M.D. Nemec, B.J. Varsho, D.G. Stump, Safety
assessment of dietary diacylglycerol oil: a two-generation reproductive
toxicity study in rats, Food Chem. Toxicol. 46 (2008) 3059–3068, http://dx.
doi.org/10.1016/j.fct.2008.06.008.
20] C.P. Chengelis, J.B. Kirkpatrick, R.H. Bruner, L. Freshwater, O. Morita, Y.
Tamaki, H. Suzuki, A 24-month dietary carcinogenicity study of DAG
(diacylglycerol) in rats, Food Chem. Toxicol. 44 (2006) 98–121, http://dx.doi.
org/10.1016/j.fct.2005.06.006.
21] T. Kasamatsu, R. Ogura, N. Ikeda, O. Morita, K. Saigo, H. Watabe, Y. Saito, H.
Suzuki, Genotoxicity studies on dietary diacylglycerol (DAG) oil, Food Chem.
Toxicol. 43 (2005) 253–260, http://dx.doi.org/10.1016/j.fct.2004.10.001.
22] K. Yasunaga, W.H. Glinsmann, Y. Seo, Y. Katsuragi, S. Kobayashi, B. Flickinger,
E.  Kennepohl, T. Yasukawa, J.F. Borzelleca, Safety aspects regarding the
consumption of high-dose dietary diacylglycerol oil in men  and women in a
double-blind controlled trial in comparison with consumption of a
triacylglycerol control oil, Food Chem. Toxicol. 42 (2004) 1419–1429, http://
dx.doi.org/10.1016/j.fct.2004.04.003.
23] BfR, Initial evaluation of the assessment of levels of glycidol fatty acid esters
detected in reﬁned vegetable fats, (2009).
24] H. Honda, K. Fujii, T. Yamaguchi, N. Ikeda, N. Nishiyama, T. Kasamatsu,
Glycidol exposure evaluation of humans who have ingested diacylglycerol oil
containing glycidol fatty acid esters using hemoglobin adducts, Food Chem.
Toxicol. 50 (2012) 4163–4168, http://dx.doi.org/10.1016/j.fct.2012.07.058.
25] H. Honda, M.  Onishi, K. Fujii, N. Ikeda, T. Yamaguchi, T. Fujimori, N.
Nishiyama, T. Kasamatsu, Measurement of glycidol hemoglobin adducts in
humans who ingest edible oil containing small amounts of glycidol fatty acid
esters, Food Chem. Toxicol. 49 (2011) 2536–2540.
26] H. Honda, M.  Törnqvist, N. Nishiyama, T. Kasamatsu, Characterization of
glycidol-hemoglobin adducts as biomarkers of exposure and in vivo dose,
Toxicol. Appl. Pharmacol. 275 (2014) 213–220.
7 gy Re
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
http://dx.doi.org/10.1007/s11746-008-1236-8.
[43] W.  Johnson, Final report on the safety assessment of trilaurin, triarachidin,22 H. Honda et al. / Toxicolo
27] NTP, (2016) Genetic toxicology evaluation of linolenic acid in
Salmonella/E.coli mutagenicity test or Ames test study (088072). Chemical
Effects in Biological Systems (CEBS). Research Triangle Park, NC (USA):
National Toxicology Program (NTP). (accessed 16.01.16.), http://tools.niehs.
nih.gov/cebs3/ntpViews/?activeTab=detail&studyNumber=002-02368-0001-
0000-2.
28] NTP, (2016), Genetic toxicology evaluation of linolenic acid in
Salmonella/E.coli mutagenicity test or Ames test study (A01298). Chemical
Effects in Biological Systems (CEBS). Research Triangle Park, NC (USA):
National Toxicology Program (NTP). (accessed 16.01.16.), http://tools.niehs.
nih.gov/cebs3/ntpViews/?studyNumber=002-02368-0002-0000-3.
29] OECD, (1997), OECD guideline for the testing of chemicals TG 471 bacterial
reverse mutation test.
30] OECD, (2014), OECD guideline for the testing of chemicals TG 487 in vitro
mammalian cell micronucleus test.
31] OECD, (2014), OECD Guideline for the Testing of Chemicals TG 474
mammalian erythrocyte micronucleus test. 10.1787/9789264224292-en.
32] T. Watanabe, M.  Shimizu, M.  Sugiura, M. Sato, J. Kohori, N. Yamada, K.
Nakanishi, Optimization of reaction conditions for the production of DAG
using immobilized 1,3-regiospeciﬁc lipase lipozyme RM IM,  J. Am.  Oil Chem.
Soc.  80 (2003) 1201–1207, http://dx.doi.org/10.1007/s11746-003-0843-5.
33] Deutsche Gesellschaft für Fettwissenschaft (DGF), Fatty-acid-bound
3-chloropropane-1,2-diol (3-MCPD) and 2,3-epoxipropane-1-ol (glycidol),
Determination in oils and fats by GC/MS (Differential measurement). DGF
Standard Method C-VI 18, (2011) 10.
34] S. MacMahon, T.H. Begley, G.W. Diachenko, Occurrence of 3-MCPD and
glycidyl esters in edible oils in the United States, Food Addit. Contam. A:
Chem. Anal. Control Expo Risk Assess. 30 (2013) 2081–2092, http://dx.doi.
org/10.1080/19440049.2013.840805.ports 3 (2016) 716–722
35] D. Gatehouse, S. Haworth, T. Cebula, E. Gocke, L. Kier, T. Matsushima, C.
Melcion, T. Nohmi, T. Ohta, S. Venitt, Recommendations for the performance
of  bacterial mutation assays, Mutat. Res. 312 (1994) 217–233.
36] M.A. Kastenbaum, K.O. Bowman, Tables for determining the statistical
signiﬁcance of mutation frequencies, Mutat. Res. 9 (1970) 527–549.
37] OECD, (2014), OECD guideline for the testing of chemicals TG 473 in vitro
mammalian chromosomal aberration test.
38] BfR, Erste Einschätzung zur Bewertung der in rafﬁnierten pﬂanzlichen Fetten
nach- gewiesenen Gehalte von Glycidol-Fettsäureestern, (2009) 1–11.
39] N. Ikeda, K. Fujii, M.  Sarada, H. Saito, M.  Kawabata, K. Naruse, K. Yuki, H.
Nakagiri, H. Honda, Y. Tamaki, N. Nishiyama, T. Kasamatsu, Genotoxicity
studies of glycidol fatty acid ester (glycidol linoleate) and glycidol, Food
Chem. Toxicol. (2012), http://dx.doi.org/10.1016/j.fct.2012.08.022.
40] T. Yamaguchi, Y. Yamashita, Mutagenic activity of autoxidized linolenic and
linoleic acid, Agric. Biol. Chem. 43 (1979) 2225–2226, http://dx.doi.org/10.
1080/00021369.1979.10863795.
41] G. Hageman, R. Kikken, F. Hoor, J. Kleinjans, Linoleic acid hydroperoxide
concentration in relation to mutagenicity of repeatedly used deep-frying fats,
Lipids 24 (1989) 899–902.
42] I. Katsuta, M. Shimizu, T. Yamaguchi, Y. Nakajima, Emission of volatile
aldehydes from DAG-rich and TAG-rich oils with different degrees of
unsaturation during deep-frying, J. Am.  Oil Chem. Soc. 85 (2008) 513–519,tribehenin, tricaprin, tricaprylin, trierucin, triheptanoin, triheptylundecanoin,
triisononanoin, triisopalmitin, triisostearin, trilinolein, trimyristin,
trioctanoin, triolein, tripalmitin, Int. J. Toxicol. 20 (2001) 61–94.
